QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration

History or presence of any clinically significant disorder of the circulatory, endocrine, neurological, digestive, respiratory, genitourinary, hematological, immunological, psychiatric, and metabolic disorders or any other disease that could interfere with the results of the study;

Abnormal screening or check-in laboratory values including inadequate renal and hepatic function as assessed by the investigator (eGFR <90 mL/min/1.73 m² calculated using CKD-EPI 2021 at screening, and total bilirubin, ALP, GGT, AST, and ALT outside normal range). A single repeat measurement is permitted for abnormal laboratory values for determining eligibility, at the discretion of the investigator.

Clinically significant abnormal physical examination, vital signs (systolic blood pressure <90 mmHg or >140 mmHg, diastolic blood pressure <50 mmHg or >90 mmHg; heart rate <50 bpm or >100 bpm; temperature 35.6°C to 37.7°C), ECG (QTcF >450ms for males and >470ms for females), or laboratory findings, as judged by the investigator. A repeat vital sign or ECG measurement, at the investigator's discretion, is acceptable for determining eligibility. Vital sign measurements may be repeated at Screening and/or Check-in, as required.

Participants with a history of specific allergies (such as urticaria, allergic asthma, etc.), or 2 or more types of allergens (such as drugs, foods such as milk and pollen), or allergies to any of soybeans, alcohol, eggs, or known allergies to components or analogues of this drug;